Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.35 |
| ▸ | KDM6A | O15550 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956745 | 1.00 | KDM4D (0.35) | KDM4DKDM6AKDM4CPTGDR2TRPV1 | |
| SCHEMBL5956615 | 0.90 | KDM4C (0.36) | KDM4DKDM6AKDM4CTRPV1HSD17B2 | |
| SCHEMBL5956670 | 0.90 | KDM4C (0.36) | KDM4DKDM6AKDM4CTRPV1HSD17B2 | |
| SCHEMBL5956487 | 0.89 | KDM4D (0.37) | KDM4DKDM6AKDM4CTRPV1HSD17B2 | |
| SCHEMBL5956779 | 0.89 | KDM4D (0.37) | KDM4DKDM6AKDM4CTRPV1HSD17B2 | |
| SCHEMBL5956673 | 0.85 | USP30 (0.39) | KDM4DKDM6ATRPV1HSD17B2 | |
| SCHEMBL5956594 | 0.81 | TRPV1 (0.34) | KDM4DKDM6ATRPV1HSD17B2 | |
| SCHEMBL5956542 | 0.81 | TRPV1 (0.34) | KDM4DKDM6ATRPV1HSD17B2 | |
| SCHEMBL4444534 | 0.80 | KDM4C (0.38) | KDM4CKDM6B | |
| SCHEMBL2855899 | 0.80 | KDM4C (0.38) | KDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | KDM4D 2364/4885KDM6A 2320/4885KDM4C 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.